Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
Meet the 5 richest eligible bachelors of India

2018-06-04 freepressjournal.in
They are young, talented, handsome, rich and ‘bachelors’. They are straight out of the Mills & Boons novel. They are no less than a prince. They are born with a silver spoon. They fly their own helicopter. They live in their own castle. They have all the luxuries in their life. They are the sons of India’s rich businessmen. Most of these ‘Princes’ have carried forward their father’s million dollar businesses.
RELCAPITAL 504093 PANAENERG 500111

0
NCLAT asks Eveready to pay over Rs17 crore in connection with CCI penalty

2018-05-09 livemint
New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Wednesday asked Eveready Industries to pay more than Rs17.1 crore in connection with an appeal moved by the company against a Rs171.55 crore penalty imposed on it by the Competition Commission of India (CCI) for cartelisation in pricing of zinc-carbon dry cell batteries.
504093 PANAENERG 531508 EVEREADY

0
Eveready shares dive nearly 11% after CCI fine

2018-04-20 thehindubusinessline
Shares of Eveready plunged nearly 11 per cent a day after fair trade regulator CCI imposed a fine of Rs 171.55 crore on the company for cartelisation in pricing of zinc-carbon dry cell batteries.
504093 PANAENERG 531508 EVEREADY

21
Market Live: Sensex weak as banks, global cues weigh; tech stocks extend rally

2018-04-20 moneycontrol
2:35 pm TCS eyes USD 100 billion in market cap: TCS is the most valued company at Dalal Street, with a market capitalisation of Rs 6.5 lakh crore and inching towards to become the first USD 100 billion company after its healthy earnings performance and strong commentary.
523229 IMXCF 500325 532939 RELIANCE HCTHY INOXLEISUR TCHQY 532538 IMAX 532755 GLKQY 532187 533605 504093 RIGD UCLQY 532281 BJJQY RLNIY 500034 GLENMARK BHARATSE YESBANK RPOWER INDUSINDBK IBN 532706 UCLQF 532648 YYBKY 532843 ULTRACEMCO TECHM ICICIBANK BAJFINANCE 532296 FORTIS PANAENERG PRAKASHCON 532174 HCLTECH

21
Market Live: Nifty Bank falls 200 pts, IT index up 4%; TCS jumps 6%, RIL HDFC drag

2018-04-20 moneycontrol
12:45 pm Market Update: The market remained under selling pressure following negative lead from global stocks. But the sharp rally in technology stocks post TCS' Q4 FY18 result and a weak rupee continued to support benchmark indices.
523229 IMXCF 500325 532939 RELIANCE HCTHY INOXLEISUR TCHQY 532538 IMAX 532755 GLKQY 532187 504093 RIGD UCLQY 532281 BJJQY RLNIY 500034 GLENMARK BHARATSE YESBANK RPOWER INDUSINDBK IBN 532706 UCLQF 532648 YYBKY 532843 ULTRACEMCO TECHM ICICIBANK BAJFINANCE 532296 FORTIS PANAENERG 532174 HCLTECH

9
Market Live: IT only gainer among sectoral indices, TCS adds Rs 40,000 cr to market cap

2018-04-20 moneycontrol
11:50 am Market Update: The market remained under selling pressure due to global weakness, but the sharp rally in technology stocks post TCS Q4 results and weak rupee capped the losses of benchmark indices.
523229 500325 532939 RELIANCE HCTHY TCHQY 532538 532755 532187 504093 RIGD UCLQY 532281 RLNIY BHARATSE YESBANK RPOWER INDUSINDBK UCLQF 532648 YYBKY 532843 ULTRACEMCO TECHM FORTIS PANAENERG HCLTECH

6
Market Live: 13-month low rupee lifts Nifty IT over 3%, but other sectoral indices down

2018-04-20 moneycontrol
10:55 am Buzzing: Eveready Industries plunged 10 percent after fair trade regulator CCI imposed a total fine of Rs 215 crore on Eveready as well as Indo National, industry grouping AIDCM and their officials for cartelisation in pricing of zinc carbon dry cell batteries.
523229 BHARATSE RPOWER 500325 532939 INDUSINDBK RELIANCE HCTHY 532538 UCLQF TCHQY 532843 532755 ULTRACEMCO TECHM 532187 FORTIS 504093 PANAENERG RIGD UCLQY HCLTECH 532281 RLNIY

0
Battery makers take Rs 215-cr CCI shock for cartelization

2018-04-20 freepressjournal.in
New Delhi : Fair trade regulator CCI on Thursday imposed a total fine of Rs 215 crore on Eveready, Indo National, industry grouping AIDCM and their officials for cartelisation in pricing of zinc carbon dry cell batteries.
504093 PANAENERG 531508 EVEREADY

0
CCI slaps Rs 215 cr fine on Eveready, Indo National, others, for unfair biz ways

2018-04-19 moneycontrol
Fair trade regulator CCI today imposed a total fine of Rs 215 crore on Eveready, Indo National, industry grouping AIDCM and their officials for cartelisation in pricing of zinc carbon dry cell batteries.
504093 PANAENERG 531508 EVEREADY

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...